Skip to main content
PMC home page
Infection and Immunity logoLink to Infection and Immunity
. 1995 Feb;63(2):509–515. doi: 10.1128/iai.63.2.509-515.1995

A mutation at histidine residue 135 of toxic shock syndrome toxin yields an immunogenic protein with minimal toxicity.

P F Bonventre 1, H Heeg 1, C K Edwards 3rd 1, C M Cullen 1
PMCID: PMC173024  PMID: 7822015

Abstract

Structure-function studies have revealed that the region between amino acids 115 and 141 of toxic shock syndrome toxin 1 (TSST-1) constitutes a biologically active domain. A critical residue appears to be histidine 135, since a site-directed mutation that alters the histidine to alanine (H135A) results in a loss of mitogenic activity and an absence of toxicity as measured in a rabbit infection model of toxic shock syndrome. We have characterized the mutant toxin further and report here on its immunogenic activity in rabbits and on the protective ability of mutant-specific antibodies in two animal models of toxin-mediated shock. Antibodies raised in rabbits by immunization with the purified H135A are fully cross-reactive with staphylococcal TSST-1 and wild-type recombinant TSST-1 (rTSST-1) expressed in Escherichia coli. The H135A antibodies neutralized the mitogenic activity for murine splenic T cells equally well as did TSST-1-specific polyclonal and monoclonal antibodies. In addition, the H135A antibodies blocked the production of tumor necrosis factor by spleen cells stimulated with rTSST-1. The toxicities of rTSST-1 and H135A were compared in D-galactosamine (D-GalNH2)-sensitized MRL-lpr/lpr mice. The nontoxicity of H135A was confirmed in this murine model of superantigen-induced septic shock. No toxicity of H135A was demonstrable at doses of 60 micrograms, while doses of rTSST-1 as low as 2 micrograms caused significant mortality within 24 to 72 h after challenge. Furthermore, subsequent to challenge of mice with H135A, no elevation in the serum levels of interleukin-2 or tumor necrosis factor was measurable. Passive immunization with H135A antibodies also protected MRL-lpr/lpr mice against lethal challenge with rTSST-1. Finally, rabbits actively immunized with purified H135A did not succumb to infection with a transformed strain of Staphylococcus aureus expressing rTSST-1. Additional animal studies will be required to confirm the immunizing potential of H135A and the efficacy of H135A antibodies as a neutralizing antitoxin.

Full Text

The Full Text of this article is available as a PDF (264.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Acharya K. R., Passalacqua E. F., Jones E. Y., Harlos K., Stuart D. I., Brehm R. D., Tranter H. S. Structural basis of superantigen action inferred from crystal structure of toxic-shock syndrome toxin-1. Nature. 1994 Jan 6;367(6458):94–97. doi: 10.1038/367094a0. [DOI] [PubMed] [Google Scholar]
  2. Bergdoll M. S., Crass B. A., Reiser R. F., Robbins R. N., Davis J. P. A new staphylococcal enterotoxin, enterotoxin F, associated with toxic-shock-syndrome Staphylococcus aureus isolates. Lancet. 1981 May 9;1(8228):1017–1021. doi: 10.1016/s0140-6736(81)92186-3. [DOI] [PubMed] [Google Scholar]
  3. Blanco L., Choi E. M., Connolly K., Thompson M. R., Bonventre P. F. Mutants of staphylococcal toxic shock syndrome toxin 1: mitogenicity and recognition by a neutralizing monoclonal antibody. Infect Immun. 1990 Sep;58(9):3020–3028. doi: 10.1128/iai.58.9.3020-3028.1990. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Bonventre P. F., Heeg H., Cullen C., Lian C. J. Toxicity of recombinant toxic shock syndrome toxin 1 and mutant toxins produced by Staphylococcus aureus in a rabbit infection model of toxic shock syndrome. Infect Immun. 1993 Mar;61(3):793–799. doi: 10.1128/iai.61.3.793-799.1993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  5. Bonventre P. F., Linnemann C., Weckbach L. S., Staneck J. L., Buncher C. R., Vigdorth E., Ritz H., Archer D., Smith B. Antibody responses to toxic-shock-syndrome (TSS) toxin by patients with TSS and by healthy staphylococcal carriers. J Infect Dis. 1984 Nov;150(5):662–666. doi: 10.1093/infdis/150.5.662. [DOI] [PubMed] [Google Scholar]
  6. Bonventre P. F., Thompson M. R., Adinolfi L. E., Gillis Z. A., Parsonnet J. Neutralization of toxic shock syndrome toxin-1 by monoclonal antibodies in vitro and in vivo. Infect Immun. 1988 Jan;56(1):135–141. doi: 10.1128/iai.56.1.135-141.1988. [DOI] [PMC free article] [PubMed] [Google Scholar]
  7. Bonventre P. F., Weckbach L., Harth G., Haidaris C. Distribution and expression of toxic shock syndrome toxin 1 gene among Staphylococcus aureus isolates of toxic shock syndrome and non-toxic shock syndrome origin. Rev Infect Dis. 1989 Jan-Feb;11 (Suppl 1):S90–S95. doi: 10.1093/clinids/11.supplement_1.s90. [DOI] [PubMed] [Google Scholar]
  8. Bonventre P. F., Weckbach L., Staneck J., Schlievert P. M., Thompson M. Production of staphylococcal enterotoxin F and pyrogenic exotoxin C by Staphylococcus aureus isolates from toxic shock syndrome-associated sources. Infect Immun. 1983 Jun;40(3):1023–1029. doi: 10.1128/iai.40.3.1023-1029.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Deresiewicz R. L., Calderwood S. B., Robertus J. D., Collier R. J. Mutations affecting the activity of the Shiga-like toxin I A-chain. Biochemistry. 1992 Mar 31;31(12):3272–3280. doi: 10.1021/bi00127a032. [DOI] [PubMed] [Google Scholar]
  10. Deresiewicz R. L., Flaxenburg J. A., Chan M., Finberg R. W., Kasper D. L. Intracellular expression of toxic shock syndrome toxin 1 in Saccharomyces cerevisiae. Infect Immun. 1994 Jun;62(6):2202–2207. doi: 10.1128/iai.62.6.2202-2207.1994. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Frankel A., Schlossman D., Welsh P., Hertler A., Withers D., Johnston S. Selection and characterization of ricin toxin A-chain mutations in Saccharomyces cerevisiae. Mol Cell Biol. 1989 Feb;9(2):415–420. doi: 10.1128/mcb.9.2.415. [DOI] [PMC free article] [PubMed] [Google Scholar]
  12. Galanos C., Freudenberg M. A., Reutter W. Galactosamine-induced sensitization to the lethal effects of endotoxin. Proc Natl Acad Sci U S A. 1979 Nov;76(11):5939–5943. doi: 10.1073/pnas.76.11.5939. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Ikejima T., Okusawa S., van der Meer J. W., Dinarello C. A. Induction by toxic-shock-syndrome toxin-1 of a circulating tumor necrosis factor-like substance in rabbits and of immunoreactive tumor necrosis factor and interleukin-1 from human mononuclear cells. J Infect Dis. 1988 Nov;158(5):1017–1025. doi: 10.1093/infdis/158.5.1017. [DOI] [PubMed] [Google Scholar]
  14. Lee P. K., Deringer J. R., Kreiswirth B. N., Novick R. P., Schlievert P. M. Fluid replacement protection of rabbits challenged subcutaneous with toxic shock syndrome toxins. Infect Immun. 1991 Mar;59(3):879–884. doi: 10.1128/iai.59.3.879-884.1991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Lee P. K., Vercellotti G. M., Deringer J. R., Schlievert P. M. Effects of staphylococcal toxic shock syndrome toxin 1 on aortic endothelial cells. J Infect Dis. 1991 Oct;164(4):711–719. doi: 10.1093/infdis/164.4.711. [DOI] [PubMed] [Google Scholar]
  16. Linnemann C. C., Jr, Staneck J. L., Hornstein S., Barden T. P., Rauh J. L., Bonventre P. F., Buncher C. R., Beiting A. The epidemiology of genital colonization with Staphylococcus aureus. Ann Intern Med. 1982 Jun;96(6 Pt 2):940–944. doi: 10.7326/0003-4819-96-6-940. [DOI] [PubMed] [Google Scholar]
  17. Marrack P., Kappler J. The staphylococcal enterotoxins and their relatives. Science. 1990 May 11;248(4956):705–711. doi: 10.1126/science.2185544. [DOI] [PubMed] [Google Scholar]
  18. Miethke T., Duschek K., Wahl C., Heeg K., Wagner H. Pathogenesis of the toxic shock syndrome: T cell mediated lethal shock caused by the superantigen TSST-1. Eur J Immunol. 1993 Jul;23(7):1494–1500. doi: 10.1002/eji.1830230715. [DOI] [PubMed] [Google Scholar]
  19. Miethke T., Wahl C., Heeg K., Echtenacher B., Krammer P. H., Wagner H. T cell-mediated lethal shock triggered in mice by the superantigen staphylococcal enterotoxin B: critical role of tumor necrosis factor. J Exp Med. 1992 Jan 1;175(1):91–98. doi: 10.1084/jem.175.1.91. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Parsonnet J., Gillis Z. A., Richter A. G., Pier G. B. A rabbit model of toxic shock syndrome that uses a constant, subcutaneous infusion of toxic shock syndrome toxin 1. Infect Immun. 1987 May;55(5):1070–1076. doi: 10.1128/iai.55.5.1070-1076.1987. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Parsonnet J., Hickman R. K., Eardley D. D., Pier G. B. Induction of human interleukin-1 by toxic-shock-syndrome toxin-1. J Infect Dis. 1985 Mar;151(3):514–522. doi: 10.1093/infdis/151.3.514. [DOI] [PubMed] [Google Scholar]
  22. Parsonnet J. Mediators in the pathogenesis of toxic shock syndrome: overview. Rev Infect Dis. 1989 Jan-Feb;11 (Suppl 1):S263–S269. doi: 10.1093/clinids/11.supplement_1.s263. [DOI] [PubMed] [Google Scholar]
  23. Schlievert P. M., Shands K. N., Dan B. B., Schmid G. P., Nishimura R. D. Identification and characterization of an exotoxin from Staphylococcus aureus associated with toxic-shock syndrome. J Infect Dis. 1981 Apr;143(4):509–516. doi: 10.1093/infdis/143.4.509. [DOI] [PubMed] [Google Scholar]
  24. Scott D. F., Kling J. M., Kirkland J. J., Best G. K. Characterization of Staphylococcus aureus isolates from patients with toxic shock syndrome, using polyethylene infection chambers in rabbits. Infect Immun. 1983 Jan;39(1):383–387. doi: 10.1128/iai.39.1.383-387.1983. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from Infection and Immunity are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES